Last reviewed · How we verify
Bioxeda (Eugenol)
Bioxeda works by binding to and inhibiting the enzyme Prostaglandin G/H synthase 1, which plays a key role in the production of inflammatory mediators.
Bioxeda, also known as Eugenol, is a standardized chemical allergen developed by HITEC-Institute of Medical Sciences. It targets Prostaglandin G/H synthase 1, a key enzyme involved in inflammation. However, its commercial status and approved indications are unknown. As a small molecule, Bioxeda's mechanism of action and pharmacokinetic properties are not well-documented. Further research is needed to understand its potential therapeutic applications and safety considerations.
At a glance
| Generic name | Eugenol |
|---|---|
| Sponsor | HITEC-Institute of Medical Sciences |
| Drug class | Standardized Chemical Allergen |
| Target | Arachidonate 5-lipoxygenase, Prostaglandin G/H synthase 1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Think of it like a fire alarm in a building. Prostaglandin G/H synthase 1 is like the alarm that sounds when there's a fire, triggering an inflammatory response. Bioxeda is like a fire extinguisher that puts out the alarm, reducing inflammation.
Approved indications
Common side effects
Key clinical trials
- Lesion Sterilization and Tissue Repair Antibiotic Paste Versus Zinc Oxide and Eugenol Pulpectomy for Treatment of Primary Molars With Pulp Necrosis (PHASE1,PHASE2)
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- Evaluation of Lesion Sterilization and Tissue Repair Techniques Versus Pulpectomy in Primary Molars With Inflammed Pulp (NA)
- Clinical and Radiographic Assessment of Neo Putty MTA Versus Formocresol Used in Vital Pulpotomy of Mandibular Primary Molars (NA)
- Effect of Graphene Oxide on Vital and Non-Vital Primary Teeth Compared to the Conventional Techniques (NA)
- Evaluation of Zinc Oxide Eugenol and Iodoform-Calcium Hydroxide as Filling Materials in Primary Molar Root Canals Prepared by Rotary and Manual Files (NA)
- THE EFFECT OF ENDODONTIC TREATMENT ON CARDIOVASCULAR RISK BIOMARKERS IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE (NA)
- Clinical and Radiographic Success Rate of Pulpotomy Versus Pulpectomy for Management of Primary Teeth With Deep Caries (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bioxeda CI brief — competitive landscape report
- Bioxeda updates RSS · CI watch RSS
- HITEC-Institute of Medical Sciences portfolio CI